Zobrazeno 1 - 10
of 79
pro vyhledávání: '"Luca Lazzari"'
Autor:
Giorgio Corti, Kristi Buzo, Enrico Berrino, Martina Miotto, Maria Costanza Aquilano, Marilena Lentini, Sara Erika Bellomo, Annalisa Lorenzato, Alice Bartolini, Gianluca Mauri, Luca Lazzari, Mariangela Russo, Federica Di Nicolantonio, Salvatore Siena, Silvia Marsoni, Caterina Marchiò, Alberto Bardelli, Sabrina Arena
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-9 (2024)
Abstract The synthetic lethal effect observed with the use of PARP inhibitors (PARPi) with tumors characterized by the loss of key players in the homologous recombination (HR) pathway, commonly referred to as “BRCAness”, is maintaining high inter
Externí odkaz:
https://doaj.org/article/b04b94e061c24ffcaaac8ebf627bb2dd
Autor:
Mariangela Russo, Simona Lamba, Annalisa Lorenzato, Alberto Sogari, Giorgio Corti, Giuseppe Rospo, Benedetta Mussolin, Monica Montone, Luca Lazzari, Sabrina Arena, Daniele Oddo, Michael Linnebacher, Andrea Sartore-Bianchi, Filippo Pietrantonio, Salvatore Siena, Federica Di Nicolantonio, Alberto Bardelli
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-12 (2018)
The emergence of sub-clones that are resistant to targeted agents is a major therapeutic obstacle in oncology. Here, using colorectal cancer as a model system, the authors show that interfering with ancestral oncogenic events present in all subclones
Externí odkaz:
https://doaj.org/article/1796a9062fbe4ab08a446eddf05ffcac
Autor:
Beth O. Van Emburgh, Sabrina Arena, Giulia Siravegna, Luca Lazzari, Giovanni Crisafulli, Giorgio Corti, Benedetta Mussolin, Federica Baldi, Michela Buscarino, Alice Bartolini, Emanuele Valtorta, Joana Vidal, Beatriz Bellosillo, Giovanni Germano, Filippo Pietrantonio, Agostino Ponzetti, Joan Albanell, Salvatore Siena, Andrea Sartore-Bianchi, Federica Di Nicolantonio, Clara Montagut, Alberto Bardelli
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-9 (2016)
Some colorectal cancer patients respond well to treatment with anti-EGFR antibodies, however response is almost invariably followed by acquired resistance. Here, the authors show that patients with shorter responses acquireRAS mutations, while those
Externí odkaz:
https://doaj.org/article/24cf071741ce4d09aa89b3a6aab76cd5
Autor:
Simona Lamba, Mariangela Russo, Chong Sun, Luca Lazzari, Carlotta Cancelliere, Wipawadee Grernrum, Cor Lieftink, Rene Bernards, Federica Di Nicolantonio, Alberto Bardelli
Publikováno v:
Cell Reports, Vol 8, Iss 5, Pp 1475-1483 (2014)
KRAS is the most frequently mutated oncogene in human cancer, yet no therapies are available to treat KRAS mutant cancers. We used two independent reverse genetic approaches to identify components of the RAS-signaling pathways required for growth of
Externí odkaz:
https://doaj.org/article/0548cbb6ffd9481ba6a3ccf3fa4e846b
Autor:
Lokha R Alagar Boopathy, Emma Beadle, Alan RuoChen Xiao, Aitana Garcia-Bueno Rico, Celia Alecki, Irene Garcia de-Andres, Kyla Edelmeier, Luca Lazzari, Mehdi Amiri, Maria Vera
Cells survive harsh environmental conditions by potently upregulating molecular chaperones such as heat shock proteins (HSPs), particularly the inducible members of the HSP70 family. The life cycle of HSP70 mRNA in the cytoplasm is unique - it is tra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84f612159cdb675f611f1ffd0f9cdd7c
Autor:
Alberto Bardelli, Salvatore Siena, Silvia Marsoni, Federica Di Nicolantonio, Giovanni Germano, Emanuela Bonoldi, Emanuele Valtorta, Federica Morano, Laura Idotta, Federica Tosi, Pietro Paolo Vitiello, Valeria Pessei, Maria Giulia Zampino, Nicola Personeni, Paolo Battuello, Gianluca Mauri, Paolo Luraghi, Alice Bartolini, Andrea Cassingena, Ludovic Barault, Marco Macagno, Alessio Amatu, Filippo Pietrantonio, Luca Lazzari, Andrea Sartore-Bianchi, Giovanni Crisafulli
Supplementary Figure from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12c88c3aa4671914cfc6cc7801152c57
https://doi.org/10.1158/2159-8290.22541308
https://doi.org/10.1158/2159-8290.22541308
Autor:
Alberto Bardelli, Salvatore Siena, Gang Li, Andrea Sartore Bianchi, Federica Di Nicolantonio, Robert Wild, Robert Shoemaker, Shunqi Yan, Roopal Patel, Nicholas Cam, Alice Bartolini, Benedetta Mussolin, Luca Novara, Giuseppe Rospo, Giorgio Corti, Luca Lazzari, Giovanni Crisafulli, Giulia Siravegna, Ge Wei, Sandra Misale, Mariangela Russo
Supplementary Figure S1. LMNA-NTRK1 genetic rearrangement detected in patient's plasma and xeno. Supplementary Figure S2. Acquisition of mutations in the TRKA kinase domain drives secondary resistance to entrectinib in Ba/F3 TRKA WT cells. Supplement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::057302585d4404e254351678a966601f
https://doi.org/10.1158/2159-8290.22531250.v1
https://doi.org/10.1158/2159-8290.22531250.v1
Autor:
Ryan B. Corcoran, Alberto Bardelli, A. John Iafrate, Salvatore Siena, Andrea Sartore-Bianchi, Ashraf Thabet, Federica Di Nicolantonio, Mari Mino-Kenudson, Theodore S. Hong, Hayley E. Robinson, Nicholas A. Jessop, Mauro Truini, Emanuele Valtorta, Luca Lazzari, Michela Buscarino, Eunice L. Kwak, Benedetta Mussolin, Leanne G. Ahronian, Giovanni Crisafulli, Giorgio Corti, Lawrence S. Blaszkowsky, Giulia Siravegna, Mariangela Russo
Supplementary Figure S1. MEK1 K57 mutation confers resistance to anti-EGFR antibodies in CRC preclinical models. Supplementary Figure S2. Dual blockade of EGFR and MEK restores sensitivity to CRC cells expressing MEK1 K57N or K57T. Supplementary Figu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f864fbbb0d95da2a6ab3b653ca62d5e
https://doi.org/10.1158/2159-8290.22531146
https://doi.org/10.1158/2159-8290.22531146
Autor:
Clara Montagut, Alberto Bardelli, Joan Albanell, Federica Di Nicolantonio, Ana Rovira, Gianni De Fabritiis, Joaquim Bellmunt, Alba Dalmases, Juan Sánchez, Marta Salido, Giovanni Crisafulli, Sebastijan Hobor, Giorgio Corti, Elena Gavilan, Mar Iglesias, Iria González, Sandra Misale, Mariangela Russo, Noelia Ferruz, Luca Lazzari, Israel Cañadas, Alejandro Martínez, Giulia Siravegna, Beatriz Bellosillo, Sabrina Arena
Purpose: Patients with colorectal cancer who respond to the anti-EGFR antibody cetuximab often develop resistance within several months of initiating therapy. To design new lines of treatment, the molecular landscape of resistant tumors must be ascer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a99b29e080404b8cca8b9c0e5f7a15a
https://doi.org/10.1158/1078-0432.c.6524322.v1
https://doi.org/10.1158/1078-0432.c.6524322.v1
Autor:
Clara Montagut, Alberto Bardelli, Joan Albanell, Federica Di Nicolantonio, Ana Rovira, Gianni De Fabritiis, Joaquim Bellmunt, Alba Dalmases, Juan Sánchez, Marta Salido, Giovanni Crisafulli, Sebastijan Hobor, Giorgio Corti, Elena Gavilan, Mar Iglesias, Iria González, Sandra Misale, Mariangela Russo, Noelia Ferruz, Luca Lazzari, Israel Cañadas, Alejandro Martínez, Giulia Siravegna, Beatriz Bellosillo, Sabrina Arena
Supplementary Table S3. Prevalence of EGFR mutations in resistant cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04c97e2237e2738caf155e1202605f49
https://doi.org/10.1158/1078-0432.22459836.v1
https://doi.org/10.1158/1078-0432.22459836.v1